Tabalumab Biosimilar - Research Grade

Human

BAFF

>1mg/ml

Human IgG4 (S228P)-kappa(S70N)

Belimumab Biosimilar - Research Grade (ICH5080)

https://www.imgt.org/mAb-DB/

ICH3002

Q9Y275

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of tabalumab, built around the same molecular target (BAFF/TNFSF13B). It is supplied for research use only and is not the clinical drug, nor is it intended for human or veterinary use. The molecule reproduces the antigen-binding specificity of the originator (a human IgG4 framework carrying the S228P hinge stabilization) so that laboratories can study BAFF engagement, ligand neutralization, and antibody-format behavior in a controlled, reproducible reagent. Typical research applications include use as a defined binding and blocking tool, as a positive control or benchmarking standard in assay development, and as scaffold material for ADCC/ADC or engineering workflows. It is offered at low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) and in bulk milligram-to-gram quantities to support in-vitro assays, screening, and preclinical model work. Because it is manufactured as a research analog rather than a licensed therapeutic, it provides a cost-effective, consistent source of a well-characterized anti-BAFF reagent for method comparison and target-biology studies. BAFF (B-cell activating factor; also BLyS, TALL-1, TNFSF13B; UniProt Q9Y275) is a type II transmembrane cytokine of the TNF superfamily, expressed largely by myeloid cells, dendritic cells, and stromal cells. It is cleaved from the surface to release a soluble form that assembles into trimers and higher-order 60-mer structures. BAFF signals through three receptors on B lineage cells: BAFF-R (TNFRSF13C), TACI (TNFRSF13B), and BCMA (TNFRSF17). Engagement, chiefly via BAFF-R, delivers survival and maturation signals to transitional and mature B cells, supporting peripheral B-cell homeostasis, selection, and immunoglobulin production. BAFF shares the receptors TACI and BCMA with the related ligand APRIL. Excess BAFF availability promotes survival of autoreactive B cells, and elevated BAFF is associated with systemic lupus erythematosus and other autoimmune conditions, making the ligand a validated target for B-cell-directed intervention.

CD257

Detects human BAFF

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Tabalumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Tabalumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Tabalumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Tabalumab that binds human BAFF.